Drug
AD109
AD109 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Phase Distribution
Ph phase_3
2
40%
Ph phase_2
3
60%
Phase Distribution
0
Early Stage
3
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (60.0%)
Phase 32 (40.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_3
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
NCT05813275
completedphase_3
Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)
NCT05811247
completedphase_2
Study That Tests AD109 in Patients Taking GLP-1 Drugs
NCT06400615
completedphase_2
Crossover Trial of AD109 in Obstructive Sleep Apnea
NCT04580394
completedphase_2
Parallel Arm Trial of AD109 and AD504 In Patients With OSA
NCT05071612
Clinical Trials (5)
Showing 5 of 5 trials
NCT05813275Phase 3
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
NCT05811247Phase 3
Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)
NCT06400615Phase 2
Study That Tests AD109 in Patients Taking GLP-1 Drugs
NCT04580394Phase 2
Crossover Trial of AD109 in Obstructive Sleep Apnea
NCT05071612Phase 2
Parallel Arm Trial of AD109 and AD504 In Patients With OSA
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5